4.6 Article

Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic

Journal

AMERICAN JOURNAL OF TRANSPLANTATION
Volume 22, Issue 3, Pages 801-812

Publisher

WILEY
DOI: 10.1111/ajt.16902

Keywords

clinical research; practice; infectious disease; infection and infectious agents; viral; kidney transplantation; nephrology; SARS-CoV-2; COVID-19; vaccine

Funding

  1. Ministry of Education, Youth and Sports of the Czech Republic, from The European Regional Development Fund [CZ.02.1.0 1/0.0/0.0/16_ 019/0000787]
  2. Lekarska Fakulta v Plzni, Univerzita Karlova [Progress Q39]

Ask authors/readers for more resources

This study found that the protection of SARS-CoV-2 mRNA vaccination against COVID-19 is limited in kidney transplant recipients, with some patients developing COVID-19 after vaccination having lower levels of anti-spike protein IgG. While some patients were able to produce higher IgG levels after COVID-19, overall humoral responses were not significant, leading to suboptimal efficacy post-vaccination.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination may fail to sufficiently protect transplant recipients against coronavirus disease 2019 (COVID-19). We retrospectively evaluated COVID-19 in kidney transplant recipients (n = 226) after BNT162b2 mRNA vaccine administration. The control group consisted of unvaccinated patients (n = 194) during the previous pandemic wave. We measured anti-spike protein immunoglobulin G (IgG) levels and cellular responses, using enzyme-linked immunosorbent spot assay, in a prospective cohort after vaccination (n = 31) and recovery from COVID-19 (n = 19). COVID-19 was diagnosed in 37 (16%) vaccinated and 43 (22%) unvaccinated patients. COVID-19 severity was similar in both groups, with patients exhibiting a comparable need for hospitalization (41% vs. 40%, p = 1.000) and mortality (14% vs. 9%, p = .726). Short posttransplant periods were associated with COVID-19 after vaccination (p < .001). Only 5 (16%) patients achieved positive SARS-CoV-2 IgG after vaccination, and 17 (89%, p < .001) recovered from COVID-19 (median IgG levels, 0.6 vs. 52.5 AU/ml, p < .001). A cellular response following vaccination was present in the majority (n = 22, 71%), with an increase in interleukin 2 secreting T cells (p < .001). Despite detectable T cell immunity after mRNA vaccination, kidney transplant recipients remained at a high risk of severe COVID-19. Humoral responses induced by vaccination were significantly lower than that after COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available